Have I been tested for all actionable mutations including EGFR, ALK, ROS1, and KRAS G12C

I appreciate you sharing your medical context, but I notice something important here: there's a mismatch between your diagnosis and the testing you're asking about.

Let me clarify:

---

🔴 Important Distinction: Your Cancer Type Matters

You have prostate cancer with several genomic findings (ATM and TP53 abnormalities, PTEN loss, and others). However, you're asking about testing for EGFR, ALK, ROS1, and KRAS G12C — these are lung cancer biomarkers, not prostate cancer biomarkers.

According to NCCN Guidelines for Metastatic Non-Small Cell Lung Cancer, these driver mutations are tested in lung adenocarcinoma, large cell carcinoma, and certain rare lung cancer types — but they're not relevant for prostate cancer evaluation.

---

✅ What SHOULD Be Tested for Prostate Cancer

For your prostate cancer, the actionable mutations you've already had tested are the correct ones:

• BRCA1/BRCA2 ✓ (you have BRCA2 tested)
• ATM ✓ (you have this — and it's abnormal, which is significant)
• TP53 ✓ (you have this — also abnormal)
• PTEN loss ✓ (you have this — abnormal)
• CDK12, CHEK2, PALB2, RAD51C ✓ (homologous recombination repair genes)

These are the homologous recombination repair (HRR) gene mutations that matter for prostate cancer treatment decisions, particularly regarding PARP inhibitors like olaparib and rucaparib.

---

🎯 Your Abnormal Findings: What They Mean

Your ATM abnormality is particularly important:

Clinical Significance:

• ATM mutations in prostate cancer may sensitize tumors to PARP inhibitors, though response rates are typically lower than BRCA1/2 mutations
• This is an OncoKB Level 2 finding, meaning there's clinical evidence supporting treatment consideration
• Your oncologist may discuss PARP inhibitor eligibility based on this finding, especially if you have metastatic castration-resistant prostate cancer (mCRPC)

Your TP53 and PTEN abnormalities also suggest more aggressive disease biology and may influence treatment sequencing.

---

❓ Questions to Ask Your Oncologist

Since you have ATM, TP53, and PTEN abnormalities:

1. "Am I eligible for PARP inhibitor therapy (olaparib or rucaparib) based on my ATM mutation?"
2. "How do my TP53 and PTEN losses affect my treatment options and prognosis?"
3. "Should I be referred to a genetic counselor given these findings?"
4. "Are there clinical trials for HRR-mutant prostate cancer I should consider?"
5. "How will you monitor my response to treatment given my genomic profile?"

---

📌 About Your Recent Questions

I also noticed you've asked about:

• Al Musella (likely referring to prostate cancer advocacy/resources)
• Glioma and MGMT methylation (these are brain cancer topics)

These don't match your prostate cancer diagnosis. Are you:

• Asking on behalf of someone else with glioma?
• Concerned about brain metastases from your prostate cancer?
• Looking for general cancer resources?

Please clarify, and I can provide more targeted information!

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.